NASDAQ$AMPH
Amphastar Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Amphastar's Q2 2024 performance was marked by solid sales growth, with BAQSIMI® emerging as a key driver.
Amphastar Pharmaceuticals reported a strong second quarter with net revenues of $182.4 million, a 25% increase compared to the same period last year. GAAP net income was $37.9 million, or $0.73 per share, while adjusted non-GAAP net income reached $48.7 million, or $0.94 per share. The company's performance was driven by solid sales growth, particularly with BAQSIMI®.
- Net revenues for Q2 2024 reached $182.4 million, a 25% increase year-over-year.
- GAAP net income for Q2 2024 was $37.9 million, or $0.73 per share.
- Adjusted non-GAAP net income for Q2 2024 was $48.7 million, or $0.94 per share.
- BAQSIMI® has emerged as a leading driver in the company's portfolio.
Headline financials
Revenue & EPS history
Amphastar · Revenue · Quarterly
$182M
Revenue by segment
Amphastar · $90.1M total across 4 segments · Q3 2023
- Glucagon$29.5M+107.5%32.8%
- Primatene MIST®$24.8M+35.3%27.6%
- Epinephrine$20.2M+3.6%22.4%
- Lidocaine$15.5M+23.0%17.2%
Forward guidance
The company is focused on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.4%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+1.3%
Avg return
30 days after
52%
27 / 52 earnings
Positive
+14.3%
Q3 2016
Best reaction
-23.8%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -26.8% | -17.4% | |
| Q4 2025 | -23.5% | -24.7% | -28.2% | |
| Q3 2025 | -4.4% | +7.3% | +5.8% | |
| Q1 2025 | +0.9% | -2.3% | +6.4% | |
| Q4 2024 | -9.7% | -10.9% | -9.7% | |
| Q3 2024 | -10.6% | -5.8% | -15.1% | |
| Q2 2024 | +11.8% | +9.8% | +15.2% | |
| Q1 2024 | -0.8% | -0.9% | -4.8% | |
| Q4 2023 | -16.0% | -15.8% | -20.8% | |
| Q3 2023 | +13.9% | +16.4% | +23.4% | |
| Q2 2023 | -1.4% | -13.3% | -18.8% | |
| Q1 2023 | +13.1% | +14.3% | +26.0% | |
| Q4 2022 | +12.6% | +11.2% | +16.1% | |
| Q3 2022 | -8.3% | -4.9% | -0.9% | |
| Q2 2022 | -12.8% | -14.0% | -22.6% | |
| Q1 2022 | +3.9% | +8.0% | +17.1% | |
| Q4 2021 | +14.0% | +15.4% | +36.7% | |
| Q3 2021 | +3.4% | +6.1% | +6.0% | |
| Q2 2021 | +0.0% | -3.5% | -7.8% | |
| Q1 2021 | +4.1% | +5.7% | +4.7% | |
| Q4 2020 | -4.8% | -6.7% | -10.1% | |
| Q3 2020 | -7.9% | -5.3% | -8.1% | |
| Q2 2020 | -4.5% | -5.7% | -5.5% | |
| Q1 2020 | +8.4% | +6.9% | +12.6% | |
| Q4 2019 | -7.3% | -5.2% | +7.6% | |
| Q3 2019 | -3.5% | -7.6% | -0.8% | |
| Q2 2019 | +7.7% | +5.5% | +10.5% | |
| Q1 2019 | -0.4% | -6.7% | -10.7% | |
| Q4 2018 | -12.8% | -14.7% | -11.6% | |
| Q3 2018 | +12.2% | +10.2% | +14.2% | |
| Q2 2018 | -3.5% | -1.0% | +8.3% | |
| Q1 2018 | -23.8% | -16.1% | -13.2% | |
| Q4 2017 | +6.3% | +4.0% | +0.4% | |
| Q3 2017 | +5.1% | -0.2% | +3.2% | |
| Q2 2017 | -2.4% | -5.6% | +0.3% | |
| Q1 2017 | -1.8% | +8.1% | +13.0% | |
| Q4 2016 | -16.6% | -6.0% | +1.0% | |
| Q3 2016 | +14.3% | +16.6% | +11.2% | |
| Q2 2016 | +12.4% | +13.3% | +19.2% | |
| Q1 2016 | +10.8% | — | — | |
| Q4 2015 | +11.9% | — | — | |
| Q3 2015 | +10.7% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q1 2015 | +7.0% | — | — | |
| Q4 2012 | +7.0% | — | — | |
| Q1 2013 | +7.0% | — | — | |
| Q4 2014 | -6.1% | — | — | |
| Q3 2014 | +7.0% | — | — | |
| Q2 2013 | -0.7% | — | — | |
| Q4 2013 | -0.7% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro